T0	Participants 49 97	in patients with pulmonary arterial hypertension
T1	Participants 169 223	in patients with pulmonary arterial hypertension (PAH)
T2	Participants 494 580	randomized patients with PAH to receive placebo or sitaxsentan 50 or 100Â mg once daily
T3	Participants 884 963	RESULTS Of 98 randomized patients, 61% were WHO functional class II at baseline
T4	Participants 1642 1709	not 6MWD in PAH patients who were mostly WHO functional class II at